Chronic Rhinosinusitis (Diagnosis) Clinical Trial
Official title:
Epigenetic Modulation Drives Chronic Type 2 Chronic Rhinosinusitis With Nasal Polyposis: Identifying Markers, Pathogens and Mechanisms
NCT number | NCT05857228 |
Other study ID # | 08.149 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 18, 2023 |
Est. completion date | December 30, 2024 |
Background/rationale While multiple disorders feature a Type 2 (T2) inflammation, triggers for T2 remains unknown. In Chronic Rhinosinusitis with Nasal Polyposis CRSwNP), a classic Type 2 disorder, dysfunction of the epithelial barrier is suggested by loss of epithelial cell differentiation, impaired response to wounding, and impairment of innate defense mechanisms. After unsuccessful attempts to describe T2 disorders solely by host genetic or environmental factors, the role of epigenetics in the modification of innate immune response and epithelial integrity appears an important unexplored mechanism for a novel appreciation of T2 disease. In addition, the investigators explore the possibility that these changes may be induced by viral pathogens. This concept has been supported by the recent observation that SARS-CoV-2 viral reduction measures resulted in a reduction of the frequency of respiratory viruses and a concomitant reduction in chronic airway disease, suggesting a role for viruses in T2 disease. Hypothesis The investigators believe T2 chronic rhinosinusitis (CRSwNP) involves epigenetic mechanisms where external factors, possibly viruses, contribute to disease via epigenetic manipulation and/or chronic viral infection. Objectives The investigators aim to identify epigenetic signatures associated with T2 CRS and explore the contribution of viruses. Method A robust methylation profiling with extensive coverage will be used for epigenome-wide association studies in T2 CRS patients assessing healthy subjects, CRS patients in remission, and diseased patients undergoing surgery. Moreover, advanced transcriptomic and metagenomic methods will identify gene expression profiles and viruses. This proposal also includes a cross-sectional study of patients undergoing surgery to assess transcriptomic patterns and epigenetics at the single-cell level. Expected outcome The investigators expect to identify epigenetic biomarkers and implicate several pathogenic viruses to open new targets for novel therapies.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - T2 CRSwNP patients with favorable evolution - T2 CRSwNP patients undergoing ESS - Healthy volonteers with no nasal symptoms and documented normal sense of smell Exclusion Criteria: - Cystic fibrosis - Primary immunodefisciencies |
Country | Name | City | State |
---|---|---|---|
Canada | CHUM | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Centre hospitalier de l'Université de Montréal (CHUM) |
Canada,
Linden D, Guo-Parke H, Coyle PV, Fairley D, McAuley DF, Taggart CC, Kidney J. Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD. Eur Respir Rev. 2019 Mar 14;28(151):180063. doi: 10.1183/16000617.0063-2018. Print 2019 Mar 31. — View Citation
Mikhail I, Grayson MH. Asthma and viral infections: An intricate relationship. Ann Allergy Asthma Immunol. 2019 Oct;123(4):352-358. doi: 10.1016/j.anai.2019.06.020. Epub 2019 Jul 2. — View Citation
North ML, Ellis AK. The role of epigenetics in the developmental origins of allergic disease. Ann Allergy Asthma Immunol. 2011 May;106(5):355-61; quiz 362. doi: 10.1016/j.anai.2011.02.008. Epub 2011 Mar 16. Erratum In: Ann Allergy Asthma Immunol. 2011 Aug;107(2):185. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of epigenetic biomarkers and pathogenic viruses | The investigators expect to identify viruses and epigenetic markers associated with CRS.
Viruses will be identified using bulk sequencing of collected tissue. Viruses will be considered "present" only if they are seen on at least 5 reads in sequencing. These identified viruses will be considered as associated with disease or healthy states assessed only when they are seen in at least 25% of tissue samples for the given condition. Association with disease will be defined as a higher proportion of candidate virus in diseased as opposed to healthy conditions. Epigenetic markers will be identified by comparing methylation profiles across the whole genome between active CRSwNP disease with disease in remission. Machine learning techniques will be used to identify putative sequences of epigenetic biomarkers associated with active disease or presence of an identified viral pathogen. |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05895929 -
The Role of IL5 in Epithelial Cell Integrity
|
Early Phase 1 | |
Completed |
NCT03673956 -
Topical Antibiotics in Chronic Rhinosinusitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT03970655 -
Functional Endoscopic Sinus Surgery Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04514120 -
Alsaleh-Javer Endoscopic Sinus Score (AJESS) System
|
N/A | |
Recruiting |
NCT03963648 -
NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP
|
N/A | |
Recruiting |
NCT05009758 -
Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps
|
N/A | |
Active, not recruiting |
NCT05553951 -
Adherence in Global Airways
|
N/A | |
Completed |
NCT03563521 -
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
|
||
Completed |
NCT05035654 -
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
|
Phase 2 | |
Withdrawn |
NCT03369574 -
Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
|
||
Recruiting |
NCT05400616 -
Nasal Microbiota Transfer Therapy in Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
|
N/A | |
Recruiting |
NCT04628442 -
Tissue Immune Interaction in Nasal Polyposis
|
||
Completed |
NCT04041609 -
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
|
Phase 2 | |
Completed |
NCT04048070 -
The Effect of Enhanced Recovery After Surgery in Endoscopic Sinus Surgery
|
N/A | |
Recruiting |
NCT03439865 -
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis
|
Early Phase 1 | |
Completed |
NCT03122795 -
Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
|
N/A | |
Recruiting |
NCT05295459 -
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
|
Phase 3 | |
Completed |
NCT04858802 -
A Clinical Evaluation of PROPEL® Contour Sinus Implant
|
N/A | |
Completed |
NCT04572516 -
Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis
|
Phase 3 | |
Completed |
NCT04595461 -
Effect of Patient Education Videos on Perioperative Anxiety in Patients Undergoing Endoscopic Sinus Surgery
|
N/A |